Catalyst
Slingshot members are tracking this event:
Kite Expects First Patient Enrollment in Q1 2017 for ZUMA-5 Study Evaluating KTE-C19 in Indolent Non-Hodgkin Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 08, 2017
Occurred Source:
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=1025235
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
First Patient Enrollment, Zuma-5, Kte-c19, Indolent Non-hodgkin Lymphoma
